

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1.-25. (Canceled)

26. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof.

27. (Canceled)

28. (Previously Presented) The method of Claim 116, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

29. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is a peptide.

30. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

31. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is selected from the group consisting of 2-tricyclyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

32. (Previously Presented) The method of Claim 116, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

33. (Previously Presented) The method of Claim 32, wherein the substance P antagonist is contained in an amount ranging from between 0.0001 to 0.1 percent by weight of the total weight of the composition.

34. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

35. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatories, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin

differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

36. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorhydrate, non-steroidal anti-parasiticals, and anti-inflammatory agents.

37. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

38. (Previously Presented) The method of Claim 37, wherein said hair care composition is selected from the group consisting of a shampoo, setting lotion, hair treatment lotion, hair cream or gel, hair colorant, restructuring lotion, permanent wave composition, and an anti-hair loss lotion or gel.

39. (Previously Presented) The method of Claim 37, wherein said mouth care composition is a toothpaste.

40. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is contained in an emulsion.

41. (Previously Presented) The method of Claim 37, wherein said mouth care composition contains an ingredient selected from the group consisting of a surfactant, thickener, wetting agent, polishing agent, fluoride, and a sweetener.

42. (Previously Presented) The method of Claim 40, wherein the emulsion contains a fatty phase, which comprises 5% to 80% by weight of the substance P antagonist-containing emulsion.

43. (Previously Presented) The method of Claim 40, wherein the emulsion contains an oil, an emulsifier, and a co-emulsifier.

44. (Previously Presented) The method of Claim 43, wherein the amount of emulsifier and co-emulsifier ranges from 0.3 to 30% by weight.

45. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

46. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

47. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

48. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered together with at least one agent selected from the group consisting of a skin differentiating modulating agent, a skin proliferation modulating agent, a skin pigmentation modulating agent, vitamin D, an estrogen, an antibacterial agent, an antiparasitic agent, an antifungal agent, an anti-inflammatory agent, an anesthetic agent, an anti-pruriginous agent, an antiviral agent, a keratolytic agent, an anti-free radical agent, an anti-seborrhea agent, an anti-dandruff agent, and an anti-acne agent.

49. (Previously Presented) The method of Claim 116, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

50. (Previously Presented) The method of Claim 49, wherein said active ingredient is selected from the group consisting of an -hydroxy acid, -hydroxy acid, -ketonic acid, -ketonic acid, retinoid, anthraline, anthranoid, peroxide, minoxidil, lithium salt, antimetabolite, and vitamin D compound.

51.-52. (Canceled)

53. (Previously Presented) The method of Claim 116, wherein said sensitive skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

54. (Previously Presented) The method of Claim 53, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.

55.-115. (Canceled)

116. (Currently Amended) A cosmetic or dermatological method for treating sensitive skin of an individual in need of such treatment, said sensitive skin having such amount of substance P already released therein as to cause neurogenic manifestations of dyesthesia caused by the release of substance P therein, said sensitive skin being characterized by exhibiting at least one symptom selected from the group consisting of tingling, prickly, itching, pruritus, overheating, discomfort,

tugging sensations, desquamation and erythema; said method comprising topically applying to said sensitive skin having such amount of substance P already released therein by exposure to and contact with at least one substance P-releasing active agent, an amount of at least one substance P antagonist effective to reduce or eliminate such amount of said already released substance P, and said at least one substance P antagonist being formulated into a topically applicable, cosmetically/dermatologically acceptable medium therefor.

117.-120. (Canceled)